Amino acid transporters such as LAT1 (SLC7A5) and ASCT2 (SLC1A5) sustain nutrient influx, engage proliferative signaling, and contribute to resistance [7,8], while exhibiting preferential tumor expression that renders them actionable targets; however, no LAT1- or ASCT2-directed agents have progressed to late-phase trials [9,10,11]. This evidence concerns the gene SLC38A7 and neoplasm.